Status:
COMPLETED
An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Lymphocytic Leukemia, Chronic
Eligibility:
All Genders
18+ years
Brief Summary
This prospective observational study will evaluate the safety of MabThera/Rituxan (rituximab) in combination with chemotherapy in patients with previously untreated or relapsed/refractory B cell-linea...
Eligibility Criteria
Inclusion
- Adult patients, \>/= 18 years of age
- B cell-lineage chronic lymphocytic leukaemia (B-CLL)
- Prescribed with MabThera/Rituxan in combination with chemotherapy according to the approved SMPC
- Informed consent to data collection
Exclusion
- Treatment with any marketed or non-marketed drug substance or experimental therapy within 4 weeks prior to first dose of study drug or participation in a clinical trial within 30 days prior to entering this study
- Any other tumour disease
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
219 Patients enrolled
Trial Details
Trial ID
NCT01224093
Start Date
October 1 2010
End Date
February 1 2014
Last Update
November 2 2016
Active Locations (55)
Enter a location and click search to find clinical trials sorted by distance.
1
Vitoria-Gasteiz, Alava, Spain, 01009
2
Alicante, Alicante, Spain, 03010
3
Elche, Alicante, Spain, 03203
4
Almería, Almeria, Spain, 04009